Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.49 |
| ▸ | ABL2 | P42684 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.43 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.43 |
| ▸ | KIT | P10721 | 3/20 | 0.42 |
| ▸ | BCR | P11274 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323133 | 0.94 | ABL1 (0.57) | ABL1ABL2FGFR1DDR1DDR2 | |
| SCHEMBL15907229 | 0.83 | KIT (0.52) | ABL1ABL2FGFR1KITKDR | |
| SCHEMBL15907247 | 0.78 | NPC1 (0.40) | ABL1KDRJAK2MAP4K4CSF1R | |
| SCHEMBL15907250 | 0.78 | NPC1 (0.37) | — | |
| SCHEMBL18323158 | 0.77 | KIT (0.62) | ABL1FGFR1KITKDREGFR | |
| Vamotinib SCHEMBL29441255 | 0.76 | ABL1 (0.80) | ABL1ABL2FGFR1DDR1DDR2 | |
| SCHEMBL14306277 | 0.76 | FGFR1 (0.69) | ABL1FGFR1KITKDRCSF1R | |
| Vamotinib SCHEMBL15789568 | 0.76 | ABL1 (0.80) | ABL1ABL2FGFR1DDR1DDR2 | |
| SCHEMBL15907237 | 0.76 | ABL1 (0.51) | ABL1ABL2FGFR1KITBCR | |
| SCHEMBL15907297 | 0.75 | KIT (0.43) | ABL1FGFR1DDR1KITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | ABL1 1/4885ABL2 2/4885FGFR1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.